Vi als, C, Conget, I, Granados, M, Sol , C, Mesa, A, Ser s-Noriega, T, Perea, V, Blanco, J, Vinagre, I, Gim nez, M, Amor, A. Impact of cardiovascular risk factors control on atherosclerosis progression in individuals with type 1 diabetes. DIABETOLOGIA. 2025; 68DOI:. PMID:. IF:10.200(Q1/1D).

Macaya, I, Ollé, L, Sánchez, E, Pérez, M, Borrell, C, Pérez, K. THE HOME CARE SERVICE IN BARCELONA AS A MODEL FOR COMMUNITY-BASED CARE SERVICES: A QUALITATIVE APPROACH. Gaceta Sanitaria. 2025; 39DOI:. PMID:. IF:1.500(Q3/7D).

Moreno, BR, Benitez, ID, Erro, M, Burgos, J, Sayés, A, Garcia-Urrestarazu, EJ, Pou, C, Castan, RA, Navarro, A, Fuentes, AMD, Lakhani, JS, Juez-Garcia, I, Manzano, C, Santisteve, S, Morales, A, Monge, A, Moncusi-Moix, A, Sánchez-Cucó, A, Alcaide, AB, de-Torres, JP, Barbé, F, Suarez-Cuartin, G, de la Rosa, D, González, J. Phenotype Analysis of Chronic Bronchial Infection Patients on Inhaled Antibiotic Therapy: A Multicentre Retrospective Cohort Study in Spain (INBREATHING Study). ARCHIVOS DE BRONCONEUMOLOGIA. 2025; 61(9)DOI:10.1016/j.arbres.2025.04.008. PMID:40350352. IF:9.200(Q1/1D).

Franquet, T, Brenes, JM, Radike, M, Giménez, A, Domingo, P. Imaging of Immunodeficiency-Associated Lymphoproliferative Disorders. SEMINARS IN ULTRASOUND CT AND MRI. 2025; 46(4)DOI:10.1053/j.sult.2025.06.001. PMID:40543829. IF:1.900(Q3/6D).

Modest, DP, Fakih, M, Salvatore, L, Esaki, T, Lopez-Bravo, DP, Taieb, J, Karamouzis, M, Ruiz-Garcia, E, Kim, TW, Kuboki, Y, Meriggi, F, Cunningham, D, Yeh, KH, Cremolini, C, Tran, Q, Chan, E, Chao, JS, Majer, IM, Pietrantonio, F. Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial. LANCET ONCOLOGY. 2025; 26(9)DOI:10.1016/S1470-2045(25)00352-3. PMID:40812325. IF:35.900(Q1/1D).

Herrera, IC, Fabregó, IE, Cols, LC, Lladó, MC, Vidal, AG, Martín, LF, Mariscal, IE, Arango, SMR, Metrallé, SCS, Alcañiz, AG. Prognostic significance of genetic biomarkers in glioblastoma IDH wild-type: a retrospective survival analysis. VIRCHOWS ARCHIV. 2025; 487DOI:. PMID:. IF:3.100(Q2/3D).

Riedell, PA, Kwon, M, Flinn, IW, Dickinson, MJ, Solano, C, Jaeger, U, Briones, J, Kato, K, Fleming, S, Bachy, E, Rambaldi, A, Shune, LO, Shah, NN, Blaise, D, Frigault, MJ, Ramakrishnan, A, Yang, A, Pearson, D, Zia, A, Segura, E, Masood, A, Barba, P. Rapcabtagene Autoleucel (YTB323) Phase 2 Trial in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL): Clinical. Clinical Lymphoma Myeloma & Leukemia. 2025; 25DOI:. PMID:. IF:2.700(Q2/4D).

Jabbour, E, Recher, C, O'Nions, J, Aldoss, I, Pierola, A, Allred, A, Alonso-Dominguez, JM, Barreyro, L, Bories, P, Curtis, M, Daskalakis, N, Della Porta, MG, Döhner, H, D'Souza, A, Dugan, JP, Reyner, JE, Exum, M, Fathi, AT, Fedele, PL, Ferrante, L, Gaj, S, Garciaz, S, Garrido, A, Paniagua, SG, Guttke, C, Gyan, E, Hiebert, B, Jentzsch, M, Kantarjian, HM, Konopleva, M, Krönke, J, Kwon, MC, Loefgren, C, Lomas, O, Mancini, V, Mantzaris, I, Martinelli, G, Giles, DM, Murphy, J, Packman, K, Papayannidis, C, Philippar, U, Platzbecker, U, Rangaraju, S, Röllig, C, Salamero, O, Sanga, M, Sauer, T, Searle, E, Tovar, N, Tucker, T, Vallet, N, Vaughan, L, Vega, G, Vyas, P, Wei, A. Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination With Intensive Chemotherapy (IC) in Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) with KMT2Ar or NPM1 Alterations. Clinical Lymphoma Myeloma & Leukemia. 2025; 25DOI:. PMID:. IF:2.700(Q2/4D).